Division of Pediatric Emergency, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung.
PhD Program in Translational Medicine, Graduate Institute of Clinical Medicine, Kaohsiung Medical University and Academia Sinica.
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619875928. doi: 10.1177/1753466619875928.
To determine the effectiveness of combined noninvasive ventilation (NIV) and mechanical insufflator-exsufflator (MI-E) for acute respiratory failure (ARF) in patients with neuromuscular disease (NMD), and outcome predictors.
A prospectively observational study of patients with ARF was conducted in a pediatric intensive care unit (PICU). All received combined NIV/MI-E during PICU stays between 2007 and 2017. Pertinent clinical variables of heart rate (HR), respiratory rate (RR), pH, PaCO, and PaO/FiO ratio were collected at baseline and at 2 h, 4-8 h, and 12-24 h after initiating use of NIV/MI-E. Treatment success was defined as avoiding intubation.
A total of 62 ARF episodes in 56 patients with NMD (median age, 13 years) were enrolled. The most frequent underlying NMD was spinal muscular atrophy (32/62, 52%). ARF was primarily due to pneumonia (65%). The treatment success rate was 86%. PICU stay and hospitalization were shorter in the success group (9.4 ± 6.1 21.9 ± 13.9 days and 16.3 ± 7.8 33.6 ± 17.9 days, respectively; both < 0.05). HR, RR, pH, and PaCO showed a progressive improvement, particularly after 4 h following successful NIV/MI-E treatment. RR decrease at 4 h, and pH increase and PaCO decrease at 4-8 h might predict success of NIV/MI-E treatment. The multivariate analysis identified PaCO at 4-8 h of 58.0 mmHg as an outcome predictor of NIV/MI-E treatment.
Applying combined NIV/MI-E in the acute care setting is an efficient means of averting intubation in NMD patients with ARF. Clinical features within 8 h of the institution may predict treatment outcome.
为了确定联合无创通气(NIV)和机械吹入-吹出气(MI-E)治疗神经肌肉疾病(NMD)患者急性呼吸衰竭(ARF)的有效性,并预测结果。
对 2007 年至 2017 年期间在儿科重症监护病房(PICU)住院的 ARF 患者进行前瞻性观察研究。所有患者在 PICU 住院期间均接受联合 NIV/MI-E 治疗。在开始使用 NIV/MI-E 后 2 小时、4-8 小时和 12-24 小时,收集心率(HR)、呼吸频率(RR)、pH 值、PaCO 和 PaO/FiO 比值等相关临床变量。治疗成功定义为避免插管。
共纳入 56 例 NMD 患者(中位年龄 13 岁)的 62 次 ARF 发作。最常见的基础 NMD 是脊髓性肌萎缩症(32/62,52%)。ARF 主要由肺炎引起(65%)。治疗成功率为 86%。成功组的 PICU 住院时间和住院时间更短(9.4±6.1 vs. 21.9±13.9 天,16.3±7.8 vs. 33.6±17.9 天,均 P<0.05)。HR、RR、pH 值和 PaCO 值逐渐改善,尤其是在成功接受 NIV/MI-E 治疗后 4 小时。RR 在 4 小时下降,pH 值在 4-8 小时升高,PaCO 值在 4-8 小时下降,可能预示着 NIV/MI-E 治疗成功。多变量分析发现,4-8 小时 PaCO 值为 58.0mmHg 是 NIV/MI-E 治疗结果的预测因素。
在急性治疗环境中应用联合 NIV/MI-E 是避免 NMD 患者 ARF 插管的有效方法。在开始治疗后 8 小时内的临床特征可能预测治疗结果。